Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine
- NEEDHAM, Mass. -- AVANT Immunotherapeutics (Nasdaq: AVAN) today reported preclinical data demonstrating positive immunogenicity and lack of immune interference for an experimental single-dose, oral vaccine combining protection from three of the most important causes of severe enteric diseases: typhoid fever, enterotoxigenic E. coli ETEC and cholera. The experimental, trivalent vaccine...
- Research articles 2007-12-05
- Boston-Area Firms Gain Little from War.
- By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Apr. 7--The stench of heated bacteria growth medium, zapped in a microwave to a temperature of 121 degrees, fills a windowless laboratory at Avant Immunotherapeutics in Needham. To a visitor, the odor is...
- Research articles 2003-04-07
- AVANT to Develop an Oral Anthrax and Plague Vaccine for U.S. Department of Defense
- Business Editors & Health/Medical Writers BIOWIRE2K NEEDHAM, Mass.--BUSINESS WIRE--Jan. 22, 2003 AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the...
- Research articles 2003-01-22
- 3M Collaborates with AVANT on Vaccine Adjuvants
- ST. PAUL, Minn. -- 3M Drug Delivery Systems announces the signing of a non-exclusive license agreement with Celldex Therapeutics, Inc. (a wholly-owned subsidiary of AVANT Immunotherapeutics). Under the agreement, 3M will provide its patented toll-like receptor TLR agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties.
- Research articles 2008-06-11
- AVANT's CholeraGarde® Vaccine Development Program Receives Further Funding from the Gates Foundation; New Support Follows Successful Phase 2 Clinical Trials
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the International Vaccine Institute ("IVI") has received $21 million in funding from the Bill & Melinda Gates Foundation for a Cholera Vaccine Initiative CHOVI, which will include conducting further clinical trials of CholeraGardeR, AVANT's cholera vaccine. Under the direction...
- Research articles 2006-08-02
- PFIZER Inc. and Avant Immunotherapeutics.(agreement to develop animal vaccines)(Brief Article)
- PFIZER Inc. and Avant Immunotherapeutics have formed an agreement to develop animal vaccines. Pfizer is paying $2.5 million in up-front licensing ... PFIZER Inc. and Avant Immunotherapeutics have formed an agreement to develop animal vaccines. Pfizer is paying $2.5 million in up-front licensing...
- Research articles 2000-12-04
- AVANT's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
- Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Tolerated in NIH-Sponsored Phase 1/2 Study
- Research articles 2007-05-18
- Vaccines Preserved with AVANT Immunotherapeutics' VitriLife Technology Show Good Stability at Room Temperature and Above
- Business Editors/Health/Medical Writers
- Research articles 2004-05-12
- Avant Immunotherapeutics Receives Key Patent for Its Cholesterol Management Vaccine, CETi-1
- Business Editors and Health/Medical Writers
- Research articles 2002-06-25
- AVANT Strengthens Its Board of Directors with the Addition of Two Vaccine Industry Leaders
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that two leading executives from the vaccine industry have joined AVANT's Board of Directors. Alf A. Lindberg, M.D., Ph.D. was formerly Executive Vice President of R&D at Pasteur Merieux Connaught now sanofi pasteur and formerly Chief Scientific Officer and Head...
- Research articles 2005-11-21
- New Congressional Defense Bill Supports Development and Purchase of Vaccines to Meet the Nation's Public Health Threats; AVANT Expects to Participate in the Development of New Vaccine Technologies to Meet These Threats
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the new Congressional defense bill, which passed today and is expected to be signed by President Bush, will provide over $3 billion for the development and purchase of vaccines, antivirals and necessary medical equipment as well as for critical...
- Research articles 2005-12-22
- Four Avant Vaccines Highlighted at 3rd International Conference on Vaccines for Enteric Diseases
- Business Editors/High-Tech Writers
- Research articles 2004-04-28
- AVANT Announces Vaccine Adjuvant Licenses with 3M
- Access to enabling TLR adjuvants to advance novel antibody-based vaccine platform
- Research articles 2008-06-11
- AVANT Immunotherapeutics and Select Vaccines Announce Partnership to Develop Improved Viral Vaccines
- Novel Virus-Like Particle Technology to be Initially Applied to Influenza Vaccines
- Research articles 2007-02-12
- AVANT Announces Start of Phase I/II Clinical Trial of Its Typhoid Fever Vaccine
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the start of a placebo-controlled, double-blind Phase I/II study of its typhoid fever vaccine candidate, Ty800. The clinical trial, sponsored by the National Institute of Allergy and Infectious Disease NIAID, a component of the National Institutes of Health NIH, is...
- Research articles 2006-02-14
- New Cholera Vaccine is Safe and Immunogenic in Infants and Children; AVANT Reports Positive Phase II Study Results of Single Dose Oral CholeraGarde®
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today a breakthrough in the control of cholera with positive preliminary results from a Phase II clinical trial of CholeraGardeR in infants and children. The researchers found the single dose, oral vaccine to be well tolerated and highly immunogenic, with 77%...
- Research articles 2005-07-27
- AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the initiation of enrollment in a randomized, placebo-controlled, double-blind Phase 2 study of its typhoid fever vaccine candidate, Ty800, in approximately 180 healthy adult volunteers. The Phase 2 study is an out-patient, dose-ranging clinical trial that will evaluate two dose...
- Research articles 2007-07-30
Additional Resources
- AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study
- NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that the double-blind, placebo-controlled multi-center Phase 2 clinical trial of its typhoid fever vaccine candidate, Ty800, met all primary endpoints. The Phase 2 study was an out-patient, dose-ranging clinical trial in 183 healthy volunteers that evaluated two dose levels of...
- Research articles 2008-04-01
- AVANT Immunotherapeutics Announces that Rotarix® Rotavirus Vaccine Has Received a Positive Opinion from the European Regulatory Authorities; Partner GlaxoSmithKline Biologicals Seeking to Commercialize Rotarix® in Europe in First Half of 2006
- NEEDHAM, Mass. -- AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner GlaxoSmithKline GSK Biologicals has received a positive opinion from the Committee for Medicinal Products for Human Use CHMP for RotarixR rotavirus vaccine. The CHMP is the Scientific Committee that evaluates the quality, safety and efficacy of medicinal products...
- Research articles 2005-12-15
- AVANT's Partner, GlaxoSmithKline, Files Rotarix® Application for U.S. Marketing Approval with the FDA
- NEEDHAM, Mass. -- AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner, GlaxoSmithKline GSK Biologicals, has filed a marketing application for the Rotarix([R]) vaccine with the United States Food and Drug Administration FDA. Rotarix([R]) is a two-dose rotavirus vaccine given to children for the prevention of gastroenteritis caused by rotavirus.
- Research articles 2007-06-27
- << Previous
- page 1 of 1
- Next >>
